Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate
Seizure - European Journal of Epilepsy, 07/05/2012
Fang J et al. – The preliminary study suggests that obese patients with epilepsy treated with sodium valproate (VPA) are at higher risk of metabolic syndrome (MetS) than individuals who are “simply obese” but otherwise well. Therefore, the HOMA index should be monitored in obese patients who receive VPA therapy, rather than monitoring body weight alone.